About Puma Biotechnology (NASDAQ:PBYI)
Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. It focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PBYI
CUSIPN/A
Phone424-248-6500
Debt
Debt-to-Equity Ratio0.91%
Current Ratio1.82%
Quick Ratio1.79%
Price-To-Earnings
Trailing P/E Ratio-7.80
Forward P/E Ratio-15.05
P/E GrowthN/A
Sales & Book Value
Annual Sales$26.20 million
Price / Sales88.18
Cash FlowN/A
Price / CashN/A
Book Value$1.42 per share
Price / Book43.13
Profitability
EPS (Most Recent Fiscal Year)($7.85)
Net Income$-291,950,000.00
Net MarginsN/A
Return on Equity-278.13%
Return on Assets-158.52%
Miscellaneous
Employees318
Outstanding Shares37,720,000
Puma Biotechnology (NASDAQ:PBYI) Frequently Asked Questions
What is Puma Biotechnology's stock symbol?
Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."
How were Puma Biotechnology's earnings last quarter?
Puma Biotechnology Inc (NASDAQ:PBYI) announced its quarterly earnings data on Thursday, March, 1st. The biopharmaceutical company reported ($1.71) EPS for the quarter, beating the consensus estimate of ($1.98) by $0.27. The biopharmaceutical company had revenue of $21.60 million for the quarter, compared to analyst estimates of $20.83 million. During the same quarter in the prior year, the firm earned ($1.22) earnings per share. View Puma Biotechnology's Earnings History.
When is Puma Biotechnology's next earnings date?
What price target have analysts set for PBYI?
9 equities research analysts have issued 1 year price objectives for Puma Biotechnology's shares. Their predictions range from $68.00 to $146.00. On average, they expect Puma Biotechnology's share price to reach $103.1111 in the next year. View Analyst Ratings for Puma Biotechnology.
Who are some of Puma Biotechnology's key competitors?
Some companies that are related to Puma Biotechnology include Hutchison China MediTech (HCM), Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO), FibroGen (FGEN), GW Pharmaceuticals (GWPH), Blueprint Medicines (BPMC), Advanced Accelerator Application (AAAP), Ligand Pharmaceuticals (LGND), Array Biopharma (ARRY), Tesaro (TSRO), Amicus Therapeutics (FOLD), Ascendis Pharma (ASND), Emergent BioSolutions (EBS), Clovis Oncology (CLVS), Evotec A.G. (EVTCY), Ultragenyx Pharmaceutical (RARE), Ironwood Pharmaceuticals (IRWD) and Supernus Pharmaceuticals (SUPN).
Who are Puma Biotechnology's key executives?
Puma Biotechnology's management team includes the folowing people:
- Alan H. Auerbach, Chairman of the Board, President, Chief Executive Officer (Age 47)
- Charles R. Eyler, Senior Vice President - Finance and Administration, Treasurer (Age 69)
- Richard P. Bryce, Chief Scientific Officer, Chief Medical Officer (Age 59)
- Steven Lo, Chief Commercial Officer (Age 50)
- Michael P. Miller, Director (Age 60)
- Jay M. Moyes, Independent Director (Age 63)
- Adrian M Senderowicz, Independent Director (Age 53)
- Troy E. Wilson Ph.D. J.D., Independent Director (Age 48)
- Frank E. Zavrl, Independent Director (Age 51)
Has Puma Biotechnology been receiving favorable news coverage?
Media coverage about PBYI stock has been trending somewhat positive this week, Accern reports. Accern ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Puma Biotechnology earned a daily sentiment score of 0.02 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 46.28 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
How do I buy shares of Puma Biotechnology?
Shares of PBYI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Puma Biotechnology's stock price today?
One share of PBYI stock can currently be purchased for approximately $61.25.
How big of a company is Puma Biotechnology?
Puma Biotechnology has a market capitalization of $2.35 billion and generates $26.20 million in revenue each year. The biopharmaceutical company earns $-291,950,000.00 in net income (profit) each year or ($7.85) on an earnings per share basis. Puma Biotechnology employs 318 workers across the globe.
How can I contact Puma Biotechnology?
Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The biopharmaceutical company can be reached via phone at 424-248-6500 or via email at [email protected]
MarketBeat Community Rating for Puma Biotechnology (PBYI)
MarketBeat's community ratings are surveys of what our community members think about Puma Biotechnology and other stocks. Vote "Outperform" if you believe PBYI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PBYI will underperform the S&P 500 over the long term. You may vote once every thirty days.
Puma Biotechnology (NASDAQ:PBYI) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
9 Wall Street analysts have issued ratings and price targets for Puma Biotechnology in the last 12 months. Their average twelve-month price target is $103.1111, suggesting that the stock has a possible upside of 68.34%. The high price target for PBYI is $146.00 and the low price target for PBYI is $68.00. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.67 | 2.78 | 2.89 | 2.89 |
| Ratings Breakdown: | 0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $103.1111 | $103.1111 | $130.6667 | $124.8889 |
| Price Target Upside: | 68.34% upside | 27.53% upside | 31.65% upside | 2.87% upside |
Puma Biotechnology (NASDAQ:PBYI) Consensus Price Target History
Puma Biotechnology (NASDAQ:PBYI) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
Puma Biotechnology (NASDAQ:PBYI) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Puma Biotechnology (NASDAQ PBYI) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 21.10%
Institutional Ownership Percentage: 95.95%
Puma Biotechnology (NASDAQ PBYI) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/22/2018 | Alan H Auerbach | Insider | Sell | 10,692 | $92.75 | $991,683.00 | 4,155,931 |  |
| 1/22/2018 | Richard Paul Bryce | SVP | Sell | 1,860 | $92.75 | $172,515.00 | 25,379 | |
| 12/1/2017 | Charles R Eyler | Insider | Sell | 1,322 | $105.46 | $139,418.12 | | |
| 9/29/2017 | Richard Paul Bryce | SVP | Sell | 15,000 | $120.00 | $1,800,000.00 | 42,239 | |
| 9/7/2017 | Richard Paul Bryce | SVP | Sell | 15,000 | $100.09 | $1,501,350.00 | 28,239 | |
| 7/20/2017 | Alan H Auerbach | Insider | Sell | 13,175 | $94.73 | $1,248,067.75 | 4,170,623 | |
| 7/20/2017 | Richard Paul Bryce | SVP | Sell | 1,998 | $94.48 | $188,771.04 | 27,246 | |
| 7/3/2017 | Richard Paul Bryce | SVP | Sell | 5,000 | $87.10 | $435,500.00 | 34,237 | |
| 6/12/2017 | Adage Capital Partners Gp, L.L | Major Shareholder | Sell | 247,260 | $80.32 | $19,859,923.20 | | |
| 6/5/2017 | Adage Capital Partners Gp, L.L | Major Shareholder | Sell | 507,128 | $87.84 | $44,546,123.52 | | |
| 5/26/2017 | Adage Capital Partners Gp, L.L | Major Shareholder | Sell | 1,235,700 | $75.38 | $93,147,066.00 | | |
| 2/1/2017 | Robert Charnas | Insider | Sell | 3,008 | $31.83 | $95,744.64 | 28,461 | |
| 1/20/2017 | Alan H Auerbach | Insider | Sell | 10,202 | $33.24 | $339,114.48 | 4,179,798 | |
| 1/20/2017 | Richard Paul Bryce | SVP | Sell | 2,293 | $33.24 | $76,219.32 | 29,237 | |
| 7/6/2015 | Richard Paul Bryce | SVP | Sell | 3,000 | $110.03 | $330,090.00 | | |
| 11/8/2013 | Adage Capital Partners Gp Llc | major shareholder | Buy | 22,549 | $38.92 | $877,607.08 | | |
| 11/5/2013 | Adage Capital Partners Gp Llc | major shareholder | Buy | 280,700 | $39.60 | $11,115,720.00 | | |
| 10/9/2013 | Adage Capital Partners Gp Llc | major shareholder | Buy | 140,900 | $40.44 | $5,697,996.00 | | |
| 12/18/2012 | Adage Capital Partners Gp Llc | Major Shareholder | Buy | 29,560 | $19.00 | $561,640.00 | | |
| 12/12/2012 | Adage Capital Partners Gp Llc | Major Shareholder | Buy | 30,400 | $19.00 | $577,600.00 | | |
| 12/11/2012 | Adage Capital Partners Gp Llc | Major Shareholder | Buy | 140,040 | $18.98 | $2,657,959.20 | | |
| 10/24/2012 | Thomas Malley | Director | Buy | 10,000 | $16.00 | $160,000.00 | | |
| 10/18/2012 | Adage Capital Partners Gp Llc | Major Shareholder | Buy | 610,000 | $16.00 | $9,760,000.00 | | |
(Data available from 1/1/2013 forward)
Puma Biotechnology (NASDAQ PBYI) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Credit Suisse Group Reiterates "Outperform" Rating for Puma Biotechnology (PBYI)
www.americanbankingnews.com - April 17 at 6:29 PM |
| Puma Biotechnology's (PBYI) Buy Rating Reaffirmed at Citigroup
www.americanbankingnews.com - April 17 at 5:27 PM |
| BidaskClub Upgrades Puma Biotechnology (PBYI) to "Strong-Buy"
www.americanbankingnews.com - April 14 at 9:51 PM |
 | The Market In 5 Minutes: Jobless Claims, Walmart-Flipkart, GE And More
www.benzinga.com - April 14 at 4:38 PM |
| Puma Biotechnology (PBYI) Stock Rating Reaffirmed by JPMorgan Chase
www.americanbankingnews.com - April 14 at 3:36 PM |
| Barclays Downgrades Puma Biotechnology (PBYI) to Equal Weight
www.americanbankingnews.com - April 12 at 11:15 AM |
| JPMorgan Chase Analysts Give Puma Biotechnology (PBYI) a $105.00 Price Target
www.americanbankingnews.com - April 11 at 1:19 PM |
| Puma Biotechnology (PBYI) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 10 at 8:55 PM |
| Puma Biotechnology (PBYI) Cut to "Hold" at BidaskClub
www.americanbankingnews.com - April 10 at 3:25 PM |
| Zacks: Analysts Anticipate Puma Biotechnology Inc (PBYI) Will Announce Quarterly Sales of $69.32 Million
www.americanbankingnews.com - April 10 at 2:17 AM |
| Zacks: Analysts Anticipate Puma Biotechnology Inc (PBYI) to Announce -$0.75 EPS
www.americanbankingnews.com - April 8 at 9:14 PM |
| Puma Biotechnology (PBYI) Upgraded by BidaskClub to "Strong-Buy"
www.americanbankingnews.com - April 8 at 9:07 AM |
 | 3 Things In Biotech, April 3: Alkermes Gets Into Trouble, Puma Gets Into Your Head, Myriad Gets Into Japan
seekingalpha.com - April 4 at 9:01 AM |
 | Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
finance.yahoo.com - April 3 at 9:11 AM |
| Puma's Shares Fall This Year Post a Solid 2017: Here's Why
finance.yahoo.com - April 2 at 4:54 PM |
 | NCCN Guidelines for Central Nervous System Cancers Include NERLYNX® (neratinib) in Combination With Capecitabine or Paclitaxel as Treatment Options for Patients With Breast ...
www.businesswire.com - April 2 at 9:26 AM |
| NCCN Guidelines for Central Nervous System Cancers Include NERLYNX® (neratinib) in Combination With Capecitabine or Paclitaxel as Treatment Options for Patients With Breast Cancer Brain Metastases
finance.yahoo.com - April 2 at 9:26 AM |
| Puma Biotechnology (PBYI) Downgraded to Sell at ValuEngine
www.americanbankingnews.com - March 31 at 12:42 PM |
| Puma Biotechnology (PBYI) PT Set at $142.00 by Credit Suisse Group
www.americanbankingnews.com - March 28 at 3:48 PM |
| Puma Biotechnology Inc (PBYI) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 28 at 11:54 AM |
| 3 Things In Biotech, March 26: A Focus On European Opinions
seekingalpha.com - March 27 at 9:18 AM |
 | Commit To Purchase Puma Biotechnology At $50, Earn 11.9% Annualized Using Options - Nasdaq
www.nasdaq.com - March 23 at 4:59 PM |
| Puma Biotechnology Inc (PBYI) Expected to Announce Earnings of -$0.75 Per Share
www.americanbankingnews.com - March 22 at 9:14 PM |
| Stifel Nicolaus Boosts Puma Biotechnology (PBYI) Price Target to $95.00
www.americanbankingnews.com - March 9 at 4:23 PM |
| Does Puma Biotechnology Inc’s (NASDAQ:PBYI) -5.79% Earnings Drop Reflect A Longer Term Trend?
finance.yahoo.com - March 9 at 9:19 AM |
| $56.88 Million in Sales Expected for Puma Biotechnology Inc (PBYI) This Quarter
www.americanbankingnews.com - March 7 at 7:45 AM |
| Puma Biotechnology to Present at Cowen’s Annual Healthcare Conference
finance.yahoo.com - March 6 at 5:10 PM |
| Sectoral Asset Management Inc Acquires New Holdings in Puma Biotechnology Inc (PBYI)
www.americanbankingnews.com - March 6 at 2:10 PM |
| Puma Biotechnology Inc (PBYI) Shares Bought by Teacher Retirement System of Texas
www.americanbankingnews.com - March 5 at 3:59 PM |
| Emory University Reduces Position in Puma Biotechnology Inc (PBYI)
www.americanbankingnews.com - March 4 at 2:59 PM |
| State of Wisconsin Investment Board Buys 6,600 Shares of Puma Biotechnology Inc (PBYI)
www.americanbankingnews.com - March 4 at 9:31 AM |
| BidaskClub Lowers Puma Biotechnology (PBYI) to Hold
www.americanbankingnews.com - March 3 at 5:48 PM |
| Puma Biotechnology (PBYI) PT Set at $106.00 by Credit Suisse Group
www.americanbankingnews.com - March 3 at 2:16 PM |
| Puma Biotechnology Inc (PBYI) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 3 at 12:05 PM |
| Why Puma Biotechnology Shares Jumped 15% Today
finance.yahoo.com - March 3 at 8:55 AM |
| EAM Investors LLC Decreases Holdings in Puma Biotechnology Inc (PBYI)
www.americanbankingnews.com - March 3 at 5:40 AM |
| 19,700 Shares in Puma Biotechnology Inc (PBYI) Purchased by Spark Investment Management LLC
www.americanbankingnews.com - March 2 at 8:54 PM |
| Puma (PBYI) Q4 Loss Narrower Than Expected, Shares Down - Nasdaq
www.nasdaq.com - March 2 at 5:33 PM |
| Puma Biotechnology (PBYI) Price Target Cut to $90.00
www.americanbankingnews.com - March 2 at 3:12 PM |
| Puma Biotechnology (PBYI) Issues Earnings Results
www.americanbankingnews.com - March 2 at 10:39 AM |
| Stock Traders Purchase Large Volume of Put Options on Puma Biotechnology (PBYI)
www.americanbankingnews.com - March 2 at 7:30 AM |
| Swiss National Bank Has $5.02 Million Position in Puma Biotechnology Inc (PBYI)
www.americanbankingnews.com - March 1 at 5:42 PM |
| Puma Biotechnology, Inc. to Host Earnings Call
finance.yahoo.com - March 1 at 5:17 PM |
| Puma Biotechnology Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 1 at 5:17 PM |
| Carillon Tower Advisers Inc. Invests $20.54 Million in Puma Biotechnology Inc (PBYI)
www.americanbankingnews.com - March 1 at 5:38 AM |
| Puma Biotechnology Inc (PBYI) Position Lifted by Wells Fargo & Company MN
www.americanbankingnews.com - February 28 at 5:24 PM |
| California Public Employees Retirement System Has $11.22 Million Position in Puma Biotechnology Inc (PBYI)
www.americanbankingnews.com - February 28 at 5:24 AM |
| Puma Biotechnology Inc (PBYI) Shares Sold by Ascend Capital LLC
www.americanbankingnews.com - February 28 at 4:44 AM |
| Blog Exposure - CHMP Recommended Against Approval of Puma Biotech's Neratinib for Extended Adjuvant Treatment of HER2-Positive Breast Cancer
finance.yahoo.com - February 27 at 8:59 AM |
| Schwab Charles Investment Management Inc. Has $13.86 Million Holdings in Puma Biotechnology Inc (PBYI)
www.americanbankingnews.com - February 27 at 5:50 AM |
Puma Biotechnology (NASDAQ:PBYI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Puma Biotechnology (NASDAQ:PBYI) Income Statement, Balance Sheet and Cash Flow Statement
Puma Biotechnology (NASDAQ PBYI) Stock Chart for Saturday, April, 21, 2018
Loading chart…
